This article was originally published in Start Up
Family-owned Direct-Haler AS has developed novel nasal and pulmonary delivery devices which allow efficient, hygienic and easy-to-use dry powder drug administration. The company's founders hope that these single-dose, disposable devices will simplify the administration of inhaled drugs and be sufficiently straightforward for potential partners to manufacture in-house.
You may also be interested in...
Convergence is the great hope of pharmaceutical and device companies hoping to enter into new high growth markets with differentiated products. Drug-eluting stents turned a stagnant product into a thriving $6 billion market, and now companies are trying to find the next large opportunity that combines devices and drugs. They're looking at many kinds of implantable devices that incorporate biomaterials and drugs to achieve site specific drug delivery, in cardiovascular disease, peripheral vascular disease, ophthalmology, orthopedics, wound healing, and anti-infection.
COVID-19 has triggered a dramatic shift toward virtual consultations and telemedicine, encouraged by more relaxed regulations and payer support.
As the global shut-down caused by the coronavirus pandemic continues, sponsors are rushing to adapt clinical trials that can move to partial or completely remote monitoring, allowing patients to remain in their homes but continue to participate in studies. And the outbreak may have another silver lining for the biopharma industry, a chance to rebuild its reputation.